IL290647A - Pemetrexed formulations - Google Patents
Pemetrexed formulationsInfo
- Publication number
- IL290647A IL290647A IL290647A IL29064722A IL290647A IL 290647 A IL290647 A IL 290647A IL 290647 A IL290647 A IL 290647A IL 29064722 A IL29064722 A IL 29064722A IL 290647 A IL290647 A IL 290647A
- Authority
- IL
- Israel
- Prior art keywords
- pemetrexed formulations
- pemetrexed
- formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title 1
- 229960005079 pemetrexed Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/018703 WO2017142556A1 (en) | 2016-02-19 | 2016-02-19 | Pemetrexed formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL290647A true IL290647A (en) | 2022-04-01 |
| IL290647B1 IL290647B1 (en) | 2023-04-01 |
| IL290647B2 IL290647B2 (en) | 2023-08-01 |
Family
ID=59625349
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312427A IL312427A (en) | 2016-02-19 | 2016-02-19 | Pemetrexed formulations |
| IL301291A IL301291A (en) | 2016-02-19 | 2016-02-19 | Pemetrexed formulations |
| IL261179A IL261179B (en) | 2016-02-19 | 2018-08-15 | Pemetrexed formulations |
| IL290647A IL290647B2 (en) | 2016-02-19 | 2022-02-15 | Pemetrexed formulations |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312427A IL312427A (en) | 2016-02-19 | 2016-02-19 | Pemetrexed formulations |
| IL301291A IL301291A (en) | 2016-02-19 | 2016-02-19 | Pemetrexed formulations |
| IL261179A IL261179B (en) | 2016-02-19 | 2018-08-15 | Pemetrexed formulations |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3416646A4 (en) |
| JP (1) | JP2019505561A (en) |
| KR (2) | KR20180132643A (en) |
| CN (1) | CN109152778B (en) |
| AU (2) | AU2016393213B2 (en) |
| CA (1) | CA3014755C (en) |
| IL (4) | IL312427A (en) |
| MX (2) | MX2018010037A (en) |
| WO (1) | WO2017142556A1 (en) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686365B2 (en) * | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| US8629152B2 (en) * | 2006-08-14 | 2014-01-14 | Sicor, Inc. | Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid |
| WO2012015810A2 (en) * | 2010-07-28 | 2012-02-02 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
| IN2012DE00912A (en) * | 2012-03-27 | 2015-09-11 | Fresenius Kabi Oncology Ltd | |
| EP2666463A1 (en) * | 2012-05-21 | 2013-11-27 | Synthon BV | Stabilized liquid composition comprising pemetrexed |
| SI2854768T1 (en) * | 2012-05-30 | 2017-08-31 | Fresenius Kabi Oncology Limited | Pharmaceutical compositions of pemetrexed |
| WO2013179310A1 (en) * | 2012-05-31 | 2013-12-05 | Mylan Laboratories Limited | Stable aqueous compositions of pemetrexed |
| JP6099557B2 (en) * | 2013-12-27 | 2017-03-22 | 富士フイルム株式会社 | Injection solution preparation and method for producing the same |
| KR101703980B1 (en) * | 2013-12-30 | 2017-02-08 | 주식회사 삼양바이오팜 | Antioxidant-free pharmaceutical composition and preparation method thereof |
| US20180235969A1 (en) * | 2014-10-16 | 2018-08-23 | Synthon B.V. | Liquid pharmaceutical composition comprising pemetrexed |
-
2016
- 2016-02-19 CA CA3014755A patent/CA3014755C/en active Active
- 2016-02-19 IL IL312427A patent/IL312427A/en unknown
- 2016-02-19 MX MX2018010037A patent/MX2018010037A/en unknown
- 2016-02-19 IL IL301291A patent/IL301291A/en unknown
- 2016-02-19 WO PCT/US2016/018703 patent/WO2017142556A1/en active Application Filing
- 2016-02-19 JP JP2018544196A patent/JP2019505561A/en not_active Withdrawn
- 2016-02-19 EP EP16890851.5A patent/EP3416646A4/en active Pending
- 2016-02-19 CN CN201680084554.1A patent/CN109152778B/en active Active
- 2016-02-19 KR KR1020187027212A patent/KR20180132643A/en not_active Application Discontinuation
- 2016-02-19 KR KR1020247009885A patent/KR20240049356A/en not_active Application Discontinuation
- 2016-02-19 MX MX2022009547A patent/MX2022009547A/en unknown
- 2016-02-19 AU AU2016393213A patent/AU2016393213B2/en active Active
-
2018
- 2018-08-15 IL IL261179A patent/IL261179B/en unknown
-
2022
- 2022-02-15 IL IL290647A patent/IL290647B2/en unknown
-
2023
- 2023-04-04 AU AU2023202089A patent/AU2023202089A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL290647B2 (en) | 2023-08-01 |
| EP3416646A1 (en) | 2018-12-26 |
| IL301291A (en) | 2023-05-01 |
| EP3416646A4 (en) | 2019-09-04 |
| MX2018010037A (en) | 2019-07-04 |
| JP2019505561A (en) | 2019-02-28 |
| CA3014755A1 (en) | 2017-08-24 |
| CN109152778A (en) | 2019-01-04 |
| IL261179B (en) | 2022-03-01 |
| CA3014755C (en) | 2023-11-14 |
| MX2022009547A (en) | 2022-09-09 |
| KR20180132643A (en) | 2018-12-12 |
| IL261179A (en) | 2018-10-31 |
| IL290647B1 (en) | 2023-04-01 |
| AU2016393213B2 (en) | 2022-03-31 |
| AU2023202089A1 (en) | 2023-06-01 |
| AU2016393213A1 (en) | 2018-10-04 |
| IL312427A (en) | 2024-06-01 |
| WO2017142556A1 (en) | 2017-08-24 |
| KR20240049356A (en) | 2024-04-16 |
| CN109152778B (en) | 2021-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | Formulations | |
| IL268697A (en) | Formulations | |
| GB2551985B (en) | Novel formulation | |
| IL269630A (en) | Niraparib formulations | |
| IL269621A (en) | Niraparib formulations | |
| IL265609A (en) | Novel formulations | |
| IL273282A (en) | Niraparib formulations | |
| GB201607918D0 (en) | Novel formulations | |
| GB201419261D0 (en) | Formulations | |
| GB201419091D0 (en) | Formulations | |
| GB201608356D0 (en) | Formulation | |
| ZA201806530B (en) | Phosphaplatin liquid formulations | |
| GB201511255D0 (en) | Formulation | |
| GB201509891D0 (en) | Formulation | |
| GB201707615D0 (en) | Formulation | |
| IL290647B1 (en) | Pemetrexed formulations | |
| PL3559185T3 (en) | Clear-rinse formulation | |
| GB201621277D0 (en) | Formulations | |
| GB201618110D0 (en) | Formulations | |
| GB201616366D0 (en) | Formulations | |
| GB201615754D0 (en) | Formulations | |
| GB201617866D0 (en) | Novel formulations | |
| GB201714461D0 (en) | Formulations | |
| GB201616509D0 (en) | Novel formulations | |
| GB201609925D0 (en) | Formulation |